

Atty. Docket No. PB60333USw

AP15 Rec'd PCT/PTO 10 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malgorzata KONIECZNA et al.

International App. No.: PCT/EP2004/007667

International Filing Date: July 8, 2004

Title: *Pharmaceutical Formulation Comprising
Levothyroxine Sodium*Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))☒ A copy of the International Search Report which issued on International Application No. PCT/EP2004/007667 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.Express Mail Label No.: EV332065902USDate of Mailing: 1/10/2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 5 January 2006
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				INT'L FILING NO.		PCT/EP2004/007667	
				INT'L FILING DATE		July 8, 2004	
				APPLICANT		Konieczna et al.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60333USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	5,955,105	9/21/1999	Mitra et al.			
	2.	5,958,979	9/28/1999	Lahr et al.			
	3.	6,190,696	2/20/2001	Groenewoud			
	4.	6,555,581	4/29/2003	Franz et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	5.	WO95/20954	8/10/1995	PCT			
	6.	WO01/74448	10/11/2001	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	7.	Hager's Handbuch de Pharmazeutischen Praxis, 5., vollständig neubearbeitete Auflage, Springer-Verlag Berlin Heidelberg pp 733-734, 1993					
	8.	Rolski, Chemia Środków Leczniczych, str. 654-655, PZWL, Warszawa 1968.					
EXAMINER				/Jake Vu/		DATE CONSIDERED 08/30/2008	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./